We sought to determine whether the amniotic cavity/fluid could be an attainable route of administration of therapeutic antibodies to the fetus/neonate.
Time-dated pregnant dams (n=9) received volume-matched intra-amniotic injections of either saline (n=29), or different concentrations of a human IgG that lacked homology with rodents: 5mg/mL (n=28); 10mg/mL (n=28); or 15mg/mL (n=24). At term, the presence of the IgG was quantified by ELISA in the serum, bone marrow, spleen, thymus, and brain of all neonates, and in the maternal serum. Statistical analysis was by median regression with significance set at Bonferroni-adjusted p
